For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.
|Articles|May 9, 2011
Intraperitoneal Struggles in Ovarian Cancer Treatments
Author(s)Fiona McCaughan, RN, MS
Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments
Advertisement
Fiona McCaughan, RN, MS, OCN, Hematology Oncology Nurse at Winchester Hospital in Stoughton, MA on Struggles Facing Intraperitoneal Ovarian Cancer Treatments
Advertisement
Related to this article
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
Prostate Cancer Care: ADT Management and APP Guidance
3
Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma
4
Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles
5